Involved Field Irradiation (IFI) Versus Elective Nodal Irradiation (ENI) for Esophageal Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01551589 |
Recruitment Status
:
Completed
First Posted
: March 13, 2012
Last Update Posted
: July 26, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Esophageal Squamous Cell Carcinoma | Radiation: Involved Field Irradiation(IFI) Drug: docetaxel and cisplatin Radiation: Elective Nodal Irradiation (ENI) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 220 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Multicenter Prospective Randomized Phase III Trial Comparing Elective to Prophylactic Regional Lymph Node Irradiation for Thoracic Esophageal Cancer |
Study Start Date : | March 2012 |
Actual Primary Completion Date : | July 2017 |
Actual Study Completion Date : | July 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Involved Field Irradiation(IFI)
Involved Field Irradiation(IFI):The clinical target volume of regional lymph node (CTVn) of IFI included the nodal region(s) in which the involved lymph node(s) was/were located.chemothrapy:docetaxel and cisplatin.
|
Radiation: Involved Field Irradiation(IFI)
Involved Field Irradiation(IFI):only irradiate positive lymph node by CT or PET-CT Radiation: IMRT IMRT is administered with chemotherapy from week 1 to week 8PTV-GTV(primary tumor):66-70Gy/33~35F,once a day, 5 times per week PTV-CTV(Clinical target,primary tumor extended 3cm in Axial):50-56Gy/33~35f,once a day, 5 times per week PTV-GTVnd(positive node):66-70Gy/33~35F,once a day, 5 times per week.
Drug: docetaxel and cisplatin
Drug: docetaxel and cisplatin.Consists of docetaxel 60-80mg/m2 day 1 and cisplatin 25mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.
Other Name: chemothrrapy
|
Active Comparator: Elective Nodal Irradiation (ENI)
Elective Nodal Irradiation (ENI):The CTVn of ENI included the involved lymph node regions and clinically uninvolved lymph nodal stations according to the location of primary tumor. Lymph node station numbers 1/2/4/5/7, 2/4/5/7 and 4/5/7/16/17 were included for upper, middle and lower thoracic ESCC in the ENI arm respectively.chemothrapy:docetaxel and cisplatin.
|
Drug: docetaxel and cisplatin
Drug: docetaxel and cisplatin.Consists of docetaxel 60-80mg/m2 day 1 and cisplatin 25mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.
Other Name: chemothrrapy
Radiation: Elective Nodal Irradiation (ENI)
The CTVn of ENI included the involved lymph node regions and clinically uninvolved lymph nodal stations according to the location of primary tumor. Lymph node station numbers 1/2/4/5/7, 2/4/5/7 and 4/5/7/16/17were included for upper, middle and lower thoracic ESCC in the ENI arm respectively.
|
- radiation pneumonitis and radiation esophagitis [ Time Frame: Acute and late toxicities of lung and esophagus were evaluated according to RTOG criteria with CT scans every 3 months for 1 years ]radiation pneumonitis and radiation esophagitis,
- 3-year Overall survival(OS) [ Time Frame: CT scans performed every 6 months for 3 years ]3-year Overall survival(OS)
- 3-year Disease-free survival [ Time Frame: CT scans every 6 months for 3 years ]3-year Disease-free survival
- Quality of life(QoL) [ Time Frame: Evaluation of quality of life every week for 3 months ]Quality of life(QoL)
- Local control rate/ Inside irrational field recurrence rate [ Time Frame: 2 year ]Evaluation after treatment 3 months and two years in the tumor local control and key observation radiation fields inside and outside the tumor recurrence and lymph node metastatic rate. To guide the rational clinical target volume of lymph node of esophageal cancer underwnet concurrent chemoradiotherapy and to Prolong the survival time, improve the quality of life of the patients.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 18 and ≤ 80
- ECOG performance status 0-2
- Weight is not less than 90% of it before treatment
- Histologically proven primary thoracic esophageal squamous cell carcinoma previously untreated stage I-III
- Chest and abdominal contrast enhanced CT within 2 weeks prior to registration(PET/CT scan is selective)
- WBC ≥ 4.0X109/L ,Absolute neutrophil count (ANC) ≥ 2.0X109/L
- Platelets ≥ 100X109/L
- Hemoglobin ≥ 90g/L(without blood transfusion)
- AST (SGOT)/ALT (SGPT) ≤ 2.5 x upper limit of normal, Bilirubin ≤ 1.5 x upper limit of normal
- Creatinine ≤ 1.5 x upper limit of normal
- Sign study-specific informed consent prior to study entry -
Exclusion Criteria:
- Multiple primary esophageal tumors
- Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years (For example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible).
-
Severe, active comorbidity, defined as follows:
- Unstable angina and/or congestive heart failure requiring hospitalization within the last 3 months
- Transmural myocardial infarction within the last 6 months
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
- Acquired immune deficiency syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
- Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception.
- Prior systemic chemotherapy, prior radiation therapy or prior target drug therapy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01551589
China, Guangxi | |
Guangxi Tumor Hospital | |
Nanning, Guangxi, China, 530021 | |
China, Guizhou | |
GuiZhou Cancer Hospital | |
Guiyang, Guizhou, China, 550000 | |
China, Sichuan | |
The Second People's Hospital of Sichuan | |
Chengdu, Sichuan, China, 610000 | |
China, Yunnan | |
Yunnan Tumor Hospital, The Third Affiliated Hospital of KUNMING Medical University | |
Kunming, Yunnan, China, 652100 |
Study Chair: | JINYI LANG, M.D. | The Second People's Hospital of Sichuan |
Responsible Party: | Chengya Chou, Chairman of Radiotherapy department, The Second People's Hospital of Sichuan |
ClinicalTrials.gov Identifier: | NCT01551589 History of Changes |
Other Study ID Numbers: |
CSWOG0001 BT-IST-SCCHN-037 ( Other Identifier: BT-IST-SCCHN-037 ) |
First Posted: | March 13, 2012 Key Record Dates |
Last Update Posted: | July 26, 2017 |
Last Verified: | July 2017 |
Keywords provided by Chengya Chou, The Second People's Hospital of Sichuan:
Esophageal squamous cell carcinoma Concurrent chemoradiotherapy Clinical target volume Safety Prognosis |
Additional relevant MeSH terms:
Carcinoma, Squamous Cell Esophageal Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Head and Neck Neoplasms |
Digestive System Diseases Esophageal Diseases Gastrointestinal Diseases Docetaxel Cisplatin Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |